Cabotegravir: all 62 studies that test it

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• Cabotegravir-Hormone PK/PD Interactions for HIV PreventionRecruitingNCT07672717Phase 1
• A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1RecruitingNCT07275606Phase 1/2
• Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject DrugsRecruitingNCT07199335Phase 4
• NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral SettingsNot yet recruitingNCT06854029Phase 4
• Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.Not yet recruitingNCT06273943Phase 3
• Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCTRecruitingNCT06250504Phase 3
• Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan AfricaNot yet recruitingNCT06133686Phase 3
• The Implementation of Pre-exposure Prophylaxis of Injectable CabotegravirRecruitingNCT05515770Phase 3
• A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult ParticipantsRecruitingNCT05418868Phase 1
• A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected ParticipantsCompletedNCT05896761Phase 3Results posted
• Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR StudyCompletedNCT05896748Phase 3Results posted
• SEARCH CAB LA Dynamic Choice HIV Prevention Study ExtensionCompletedNCT05549726Phase 4Results posted
• A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE TerritoriesCompletedNCT05514509Phase 4Results posted
• A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United StatesCompletedNCT05374525Phase 4Results posted
• Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent FemalesCompletedNCT04824131Phase 2Results posted
• Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent MalesCompletedNCT04692077Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically SuppressedCompletedNCT04542070Phase 3Results posted
• Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult ParticipantsCompletedNCT04484337Phase 1Results posted
• A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European CountriesCompletedNCT04399551Phase 3Results posted
• Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult ParticipantsCompletedNCT04371380Phase 1Results posted
• Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1CompletedNCT03739996Phase 2Results posted
• Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE StudyCompletedNCT03639311Phase 2Results posted
• The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifECompletedNCT03635788Phase 3Results posted
• More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and AdolescentsCompletedNCT03497676Phase 1/2Results posted
• Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsActive, not recruitingNCT03299049Phase 3Results posted
• Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected WomenActive, not recruitingNCT03164564Phase 3Results posted
• Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy SubjectsCompletedNCT03149848Phase 1Results posted
• Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsActive, not recruitingNCT02951052Phase 3Results posted
• Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsActive, not recruitingNCT02938520Phase 3Results posted
• Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With MenCompletedNCT02720094Phase 2/3Results posted
• Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult VolunteersCompletedNCT02478463Phase 1Results posted
• Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected AdultsCompletedNCT02178800Phase 2Results posted
• A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult SubjectsCompletedNCT02120352Phase 2Results posted
• Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus RilpivirineCompletedNCT01641809Phase 2Results posted
• Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)CompletedNCT00920426Phase 2Results posted
• A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIVActive, not recruitingNCT06970223Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy AdultsActive, not recruitingNCT06786520Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)Active, not recruitingNCT06741397Phase 2
• Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+RilpivirineCompletedNCT06185452Phase 4
• Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South AfricaActive, not recruitingNCT06138600Phase 3
• Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)Active, not recruitingNCT06134362Phase 3
• A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)Active, not recruitingNCT05996471Phase 2
• Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in BotswanaActive, not recruitingNCT05986084Phase 4
• A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral TherapyCompletedNCT05917509Phase 3
• A Study of a Rilpivirine Extended-Release Suspension in Healthy ParticipantsCompletedNCT05112939Phase 1
• A Study to Evaluate the Effect of High Fat Meal on CabotegravirCompletedNCT02799264Phase 1
• Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South AfricaWithdrawnNCT02462772Phase 2
• A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy VolunteersCompletedNCT02354950Phase 1
• Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal ImpairmentCompletedNCT02354937Phase 1
• Relative Bioavailability Study of Phase III Tablet Formulation of CabotegravirCompletedNCT02345707Phase 1
• Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female SubjectsCompletedNCT02159131Phase 1
• A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult SubjectsCompletedNCT02059031Phase 1
• Study to Evaluate the Effect of GSK1265744 on Cardiac ConductionCompletedNCT02027454Phase 1
• An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult SubjectsCompletedNCT01848340Phase 1
• A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy SubjectsCompletedNCT01756131Phase 1
• A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult SubjectsCompletedNCT01754116Phase 1
• Relative Bioavailability Study of GSK1265744 FormulationsCompletedNCT01648257Phase 1
• A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult SubjectsCompletedNCT01593046Phase 1
• A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult SubjectsCompletedNCT01467531Phase 1
• DDI Study of Etravirine and GSK1265744CompletedNCT00920296Phase 1
• Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.CompletedNCT00812318Phase 1
• A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744CompletedNCT00659191Phase 1

← Cabotegravir overview